Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

BACKGROUND: Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for durvalumab in routine clinical practice. METHODS: We evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Boys, Emma, Gao, Bo, Hui, Rina, da Silva, Inês, Hau, Eric, Gee, Harriet, Nagrial, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968599/
https://www.ncbi.nlm.nih.gov/pubmed/36627112
http://dx.doi.org/10.1111/1759-7714.14780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968599/
https://www.ncbi.nlm.nih.gov/pubmed/36627112
http://dx.doi.org/10.1111/1759-7714.14780

Ejemplares similares